Susan D. Wyrick - 02 Mar 2026 Form 4 Insider Report for Sana Biotechnology, Inc. (SANA)

Role
SVP, Finance and Accounting and Principal Accounting Officer
Signature
/s/ Aaron M. Grossman, Attorney-in-Fact for Susan D. Wyrick
Issuer symbol
SANA
Transactions as of
02 Mar 2026
Net transactions value
$0
Form type
4
Filing time
04 Mar 2026, 16:17:38 UTC
Previous filing
06 Jan 2026
Next filing
06 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Wyrick Susan D. SVP, Finance and Accounting and Principal Accounting Officer C/O SANA BIOTECHNOLOGY, INC., 188 EAST BLAINE STREET, SUITE 350, SEATTLE /s/ Aaron M. Grossman, Attorney-in-Fact for Susan D. Wyrick 04 Mar 2026 0001568605

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SANA Common Stock Options Exercise +1,525 +0.82% $0.000000* 187,408 02 Mar 2026 Direct
transaction SANA Common Stock Tax liability -491 -0.26% $3.91* 186,917 03 Mar 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SANA Restricted Stock Units Options Exercise -1,525 -50% $0.000000* 1,525 02 Mar 2026 Common Stock 1,525 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.
F2 The award vested as to 25% of the restricted stock units on each of March 2, 2024, 2025 and 2026, and the remaining restricted stock units will vest on March 2, 2027, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date.

Remarks:

SVP, Finance and Accounting and Principal Accounting Officer